病毒学
鼻腔给药
病毒
甲型流感病毒
生物
流感减毒活疫苗
H5N1亚型流感病毒
接种疫苗
流感疫苗
大流行
医学
2019年冠状病毒病(COVID-19)
传染病(医学专业)
疾病
病理
作者
Jae-Keun Park,Sharon Fong,Louis M. Schwartzman,Zhong-Mei Sheng,Ashley Freeman,Lex Matthews,Yongli Xiao,Mitchell D. Ramuta,Natalia A. Batchenkova,Li Qi,Luz Angela Rosas,Stephanie L. Williams,Kelsey Scherler,Monica Gouzoulis,Ian Bellayr,David M. Morens,Kathie‐Anne Walters,Matthew J. Memoli,John C. Kash,Jeffery K. Taubenberger
标识
DOI:10.1101/2021.09.10.459807
摘要
Abstract Influenza A viruses (IAVs) present major public health threats from annual seasonal epidemics, from pandemics caused by novel virus subtypes, and from viruses adapted to a variety of animals including poultry, pigs and horses. Vaccines that broadly protect against all such IAVs, so-called “universal” influenza vaccines, do not currently exist, but are urgently needed. This study demonstrates that an inactivated, multivalent whole virus vaccine, delivered intramuscularly or intranasally, is broadly protective against challenges with multiple IAV HA/NA subtypes in both mice and ferrets, including challenges with IAV subtypes not contained in the vaccine. This vaccine approach indicates the feasibility of eliciting broad “universal” IAV protection, and identifies a promising candidate for influenza vaccine clinical development. One-Sentence Summary An inactivated, whole avian influenza virus vaccine delivered intramuscularly or intranasally provides extremely broad protection against antigenically divergent viral challenge and is a promising candidate for a “universal” influenza virus vaccine.
科研通智能强力驱动
Strongly Powered by AbleSci AI